Table 2

Characteristics of patients with GPA

Baseline cytokine secretion

Stimulation


n

%

n

%


Biopsy proof

GPA

12

60

7

70


EULAR subgroups

generalized

14

70

8

80

early systemic

5

25

1

10

local

1

5

0

0

severe

0

0

1

10


EULAR disease activity

remission

6

30

2

20

response

0

0

1

10

relapse, minor

8

40

2

20

relapse, major

4

20

3

30

refractory

1

5

0

0

low-activity

1

5

2

20


Endoscopy: endonasal activity

none

12

60

4

40

mild

7

35

4

40

moderate

0

0

2

20

not evaluated

1

5

0

0


Disease scores

median (range)

median (range)

DEI

2 (0 to 5)

2 (0 to 5)

BVAS-1

3 (0 to 13)

1.5 (0 to 12)

BVAS-2

0 (0 to 4)

0 (0 to 4)

VDI

0.5 (0 to 3)

2 (0 to 4)


Immunomodulating therapy

n (%)

mean value (mg)

n (%)

mean value (mg)

prednisolone

19 (95)

12.89

9 (90)

10.67

methotrexate

10 (50)

22.25

2 (20)

20

cyclophosphamide regular

3 (15)

133.33

1 (10)

100

cyclophosphamide bolus

2 (10)

1000

2 (20)

1000

azathioprine

2 (10)

125

2 (20)

125

leflunomide

2 (10)

25

2 (20)

25

mycophenolate mofetil

1 (5)

2000

0 (0)

0

cummulative cyclophosphamide

6 (30)

45.17 (g)

8 (80)

14.88 (g)


Wohlers et al. Arthritis Research & Therapy 2012 14:R203   doi:10.1186/ar4041

Open Data